¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen antibody interaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® carcinoembryonic antigen ÇÑ±Û ¾Ï¹è¾ÆÇ׿ø
¼³¸í   
  ¿ø·¡ Å¾ÆÀÇ ÀåÁ¶Á÷¿¡¼­ Á¤»óÀûÀ¸·Î Á¸ÀçÇϴ ¹°Áú·Î Å¾Ʊâ ÀÌÈÄ¿¡´Â Á¸ÀçÇÏÁö ¾Ê´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª À§, °£, ÇãÆÄ µîÀÇ ¾ÏÀÌ Àִ °æ¿ì¿¡ ¼ºÀο¡¼­µµ Á¸ÀçÇÑ´Ù. À̸¦ ÀÌ¿ëÇØ¼­ ¾ÏÀÇ Ä¡·áÈ¿°ú ÆÇÁ¤À̳ª Àç¹ß¿©ºÎÀÇ Á¶»ç¿¡ ÀÌ¿ëÇÑ´Ù.
¿µ¹® antiglobulin antibody ÇÑ±Û Çױ۷κҸ°Ç×ü
¼³¸í   
  Ç×ü¿¡ ´ëÇÑ Ç×ü, Áï Æ¯Á¤ Ç×ü¿Í °áÇÕÇÒ ¼ö Àִ Ç×ü. ´ë°³ Àΰ£ÀÇ Ç×ü¸¦ Áã¿¡ ÁÖ»çÇÏ¿© Áã·Î ÇÏ¿©±Ý Àΰ£ Ç×ü¿¡ ´ëÇÑ Ç×ü¸¦ ¸¸µé°Ô ÇÑ´Ù(Áã¿¡ À־´Â Àΰ£ÀÇ Ç×üµµ ¿ÜºÎ¿¡¼­ µé¾î¿Â ¹°ÁúÀ̹ǷÎ). À̰ÍÀº ¿©·¯ °¡Áö ½ÇÇè¿¡¼­ Àΰ£ÀǠƯÁ¤Ç×ü¸¦ °ËÃâÇϴµ¥ ÀÌ¿ëÇÑ´Ù.
¿µ¹® antigen ÇÑ±Û Ç׿ø
¼³¸í   
  Æ¯ÀÌÇÑ ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö Àִ ¾î¶°ÇÑ ¹°Áú. ¿©±â¿¡¼­ ¸»Çϴ ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ̶õ ºñƯÀÌÀûÀΠ¸é¿ª¹ÝÀÀ°ú´Â ¹Ý´ëµÇ´Â Àǹ̷Π±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ Ç×ü³ª ±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ ¼¼Æ÷¸¦ ¸¸µå´Â °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® antibody ÇÑ±Û Ç×ü
¼³¸í   
  »ç¶÷ÀÇ ¸ö¿¡¼­ ¸é¿ª¿¡ °ü°èÇϴ ¹°Áú. ¿ÜºÎ¿¡¼­ µé¾î¿Â ¹°Áú°ú ²À ¸Â°Ô °áÇÕÀ» ÇÏ¿©¼­ ±× ¹°ÁúÀÇ »ý¹°ÇÐÀû È°µ¿À» ¾ïÁ¦Çϰųª ÆÄ±«Çϰųª »ç¶÷ÀÇ ´Ù¸¥ ¸é¿ª¼¼Æ÷·Î ÇÏ¿©±Ý °ø°ÝÇϱ⠿ëÀÌÇÏ°Ô ÇØÁִ ±â´ÉÀ» °¡Áö°í ÀÖ´Ù. Ç×ü´Â ¸é¿ª±Û·ÎºÎ¸°À̶ó´Â °ÍÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ°í ±× ÇüÅ¿¡ µû¶ó IgA, IgE, IgG, IgDµîÀ¸·Î ³ª´«´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • additive interaction
    »ó°¡ÀÛ¿ë
  • binocular interaction
    µÎ´«»óÈ£ÀÛ¿ë, ¾ç¾È»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • genetic interaction
    À¯Àü»óÈ£ÀÛ¿ë
  • infant-mother interaction
    ¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë
  • orbit interaction
    ±Ëµµ»óÈ£ÀÛ¿ë
  • primary interaction
    ÀÏÂ÷»óÈ£ÀÛ¿ë
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
  • radiation interaction
    ¹æ»ç¼±»óÈ£ÀÛ¿ë
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interaction
    »óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • carcinoembryonic antigen
    ¾ÏÁ¾¹è¾ÆÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • sequestered antigen
    °Ý¸®Ç׿ø
  • somatic antigen
    ü¼¼Æ÷Ç׿ø, ±ÕüÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • tumor antigen
    Á¾¾çÇ׿ø
  • antigen excess
    Ç׿ø°úÀ×
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • additive interaction
    »ó°¡ÀÛ¿ë
  • binocular interaction
    ¾ç¾È»óÈ£ÀÛ¿ë, µÎ´«»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • genetic interaction
    À¯Àü»óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë
  • infant-mother interaction
    ¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
  • orbit interaction
    ±Ëµµ»óÈ£ÀÛ¿ë
  • primary interaction
    ÀÏÂ÷»óÈ£ÀÛ¿ë
  • radiation interaction
    ¹æ»ç¼±»óÈ£ÀÛ¿ë
  • receptor-ligand interaction
    ¼ö¿ëü¹èÀ§ÀÚ»óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody interaction
    Ç׿ø-Ç×ü»óÈ£ÀÛ¿ë
  • J-coupling interaction
    J °áÇÕ »óÈ£ÀÛ¿ë
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • additive interaction
    »ó°¡(ßÓÊ¥)ÀÛ¿ë.
  • genetic interaction
    À¯ÀüÀû »óÈ£ÀÛ¿ë
  • heme heme interaction
    Èû-Èû »óÈ£ÀÛ¿ë(¡­ßÓû»íÂéÄ).
  • heme heme interaction
    Çð-Çð »óÈ£ÀÛ¿ë(¡­ßÓû»íÂéÄ).
  • infant-mother interaction
    ¿µ¾Æ-¸ð »óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ).
  • interaction
    »óÈ£ÀÛ¿ë
  • interaction, T-B cell
    T¼¼Æ÷-B¼¼Æ÷ »óÈ£ÀÛ¿ë
  • interaction, T-T cell
    T¼¼Æ÷°£ »óÈ£ÀÛ¿ë
  • interaction, primary
    ÀÏÂ÷»óÈ£ÀÛ¿ë
  • photon interaction
    ±¤ÀÚ»óÈ£ÀÛ¿ë
  • radiation interaction
    ¹æ»ç¼± »óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody interaction
    Ç׿ø-Ç×ü»óÈ£ÀÛ¿ë
  • antigen-antibody complex
    Ç׿ø-Ç×üº¹ÇÕü
  • antigen-antibody complex, soluble
    ¼ö¿ë¼º Ç׿ø-Ç×üº¹ÇÕü
  • antigen-antibody reaction
    Ç׿ø-Ç×ü¹ÝÀÀ
  • soluble antigen fluorescent antibody test
    °¡¿ëÇ׿øÇü±¤Ç×ü½ÃÇè
  • soluble antigen-antibody complex
    °¡¿ë¼º Ç׿øÇ×üº¹ÇÕü(¡­ù÷ê«ù÷ô÷ÜÜùêô÷).
  • capsular antigen =K. antigen
    Çù¸·Ç׿ø(¡­ù÷ê«).
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • additive interaction
    »ó°¡(ßÓÊ¥)ÀÛ¿ë.
  • binocular interaction
    ¾ç¾È»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cellular interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • dipole dipole interaction
    ½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹° »óÈ£ÀÛ¿ë
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • circumsporozoite antigen
    Æ÷ÀÚ¼ÒüÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • excretory-secretory antigen
    ºÐºñ¹è¼³Ç׿ø
  • metabolic antigen
    ´ë»çÇ׿ø
  • somatic antigen
    üÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • complementary interaction
    »óº¸¼º »óÈ£ÀÛ¿ë(ßÓÜÍàõßÓû»íÂéÄ)
  • crossed hydrophobic interaction immunoelectrophoresis ±³Â÷ ¼Ò¼ö¼º»óÈ£ÀÛ¿ë ¸é¿ªÀü±â¿µµ¿(Îßó©áÂâ©àõßÓû»íÂéÄØóæ¹ï³Ñ¨ç¶
    ÔÑ)
  • dipole-dipole interaction
    ½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£ÀÛ¿ë(äªÐ¿í­äªÐ¿í­ßÓû»íÂéÄ)
  • dipole-induced dipole interaction
    ½Ö±ØÀÚÀ¯µµ ½Ö±ØÀÚ »óÈ£ÀÛ¿ë(äªÐ¿í­ë¯ÓôäªÐ¿í­ßÓû»íÂéÄ)
  • hydrophobic interaction
    ¼Ò¼ö »óÈ£ÀÛ¿ë(áÂâ©ßÓû»íÂéÄ)
  • hydrophobic interaction chromatography
    ¼Ò¼ö »óÈ£ÀÛ¿ë(áÂâ©ßÓû»íÂéÄ) Å©·Î¸¶Åä±×·¡ÇÇ
  • ion-dipole interaction
    ÀÌ¿Â-½Ö±ØÀÚ(äªÐ¿í­) »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)
  • ion induced dipole interaction
    "ÀÌ¿ÂÀ¯µµ(ë¯Óô) ½Ö±ØÀÚ(äªÐ¿í­), »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)"
  • ion-ion interaction
    ÀÌ¿Â-À̿ »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)
  • long-range interaction
    ¿ø°Å¸® »óÈ£ÀÛ¿ë(êÀËå×îßÓû»íÂéÄ)
  • lyophobic interaction
    ¼Ò¾×»óÈ£ÀÛ¿ë(áÃäûßÓû»íÂéÄ)
  • nonbonding interaction
    ºñ°áÇÕ»óÈ£¹ÝÀÀ(ު̿ùêßÓû»Úãëë)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • agglutination antibody titer
    ÀºÁýÇ×ü¿ª°¡
  • antibody
    Ç×ü
  • antigen
    Ç׿ø
  • HLA antigen
    HLAÇ׿ø
  • HLA[=human leukocyte antigen]
    HLAÇ׿ø, Àΰ£¹éÇ÷±¸Ç׿ø
  • homologous antigen
    »óµ¿Ç׿ø
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • dipole dipole interaction
    ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • intermolecular dipole dipole interaction
    ºÐÀÚ°£½Ö±ØÀÚ°£»óÈ£ÀÛ¿ë
  • intramolecular dipole dipole interaction
    ºÐÀÚ³»½Ö±ØÀÚ°£»óÈ£ÀÛ¿ë
  • J-coupling interaction
    J°áÇÕ»óÈ£ÀÛ¿ë
  • proton electron dipole dipole interaction
    ¾çÀÚÀüÀÚ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£¹ÝÀÀ
  • proton proton dipole dipole interaction
    ¾çÀÚ¾çÀÚ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£¹ÝÀÀ
  • tissue interaction
    Á¶Á÷°£ÀÇ »óÈ£ÀÛ¿ë
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HLA histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod...
ACA abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino...
HA H antigen; Hakim-Adams [syndrome]; halothane anesthesia; Hartley [guinea pig]; headache; health alli...
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
LALI lymphocyte antibody-lymphocytolytic interaction
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BI Binaural Interaction
BIA Biomolecular Interaction Analysis
BIA Biospecific Interaction Analysis
HCI Human Computer Interaction
HIC Hydrophobic Interaction Chromatography
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
  • additive interaction
    »ó°¡ ÀÛ¿ë
  • heme heme interaction
    Èû-Èû »óÈ£ÀÛ¿ë
  • high-power interaction
    °íÃâ·Â »óÈ£ ÀÛ¿ë
  • interaction
    »óÈ£ ÀÛ¿ë
    µÎ °³ ¶Ç´Â ±× ÀÌ»óÀÌ ¼­·Î ¼­·Î ÀÛ¿ëÇÏ´Â ¼ºÁú, »óųª °úÁ¤.
  • nonthermal interaction
    ºñ¿­ »óÈ£ÀÛ¿ë
  • photochemical interaction
    ±¤È­ÇÐ ¹ÝÀÀ
  • photothermal interaction
    ±¤¿­ ¹ÝÀÀ
  • proton proton dipole dipole interaction
    ¾çÀÚ ¾çÀÚ ½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£ ¹ÝÀÀ
  • triple interaction
    »ïÁß »óÈ£ ÀÛ¿ë
  • accessible antigen
    Á¢±Ù °¡´É Ç׿ø, ±ÙÁ¢ Ç׿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
Forssman antigen-antibody reaction The combination of Forssman antibody with heterogenetic antigen of the Forssman type, as in the agglutination of sheep erythrocytes (which contain Forssman antigen) by serum from a person with infectious mononucleosis which contains Forssman antibody.
Synonym: Forssman reaction.
(05 Mar 2000)
apolar interaction <chemistry> The attractive force between molecules due to the close positioning of non-hydrophilic portions of the two molecules.
(09 Oct 1997)
hydrophobic interaction <chemistry> The attractive force between molecules due to the close positioning of non-hydrophilic portions of the two molecules.
(09 Oct 1997)
specimen interaction <microscopy> Reactions that occur inside the specimen when being struck with a beam of energetic electrons or ions.
(05 Aug 1998)
specimen interaction volume <microscopy> The volume inside the specimen in which all specimen interactions occur during electron beam irradiation.
(05 Aug 1998)
DNA-protein interaction <molecular biology> Any complex that forms between a protein molecule and DNA.
Examples are nucleosomes (structures formed for the purpose of DNA storage) and any gene regulatory protein (a protein which regulates transcription by binding to a regulatory region on the DNA).
(09 Oct 1997)
drug-drug interaction The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity.
(09 Oct 1997)
drug interaction <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other.
(18 Jul 2002)
interaction The quality, state or process of (two or more things) acting on each other.
(18 Nov 1997)
interaction process analysis In psychology, analysis of small group behaviour in terms of 12 specific categories, e.g., solidarity, tension release, agreement.
(05 Mar 2000)
affinity antibody The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible.
(05 Mar 2000)
agglutinating antibody 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen.
Synonym: agglutinating antibody, immune agglutinin.
2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin.
(05 Mar 2000)
anaphylactic antibody Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain.
See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test.
Synonym: anaphylactic antibody, cytophilic antibody.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody
    Ç×µ¶¼Ò; Ç×ü
  • interaction
    »óÈ£ÀÛ¿ë
  • antibody
    Ç×µ¶¼Ò;(Ç÷¾× ÁßÀÇ)Ç×ü
  • drug interaction
    (¾à)¾à¹° »óÈ£ ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë;»óÈ£ÀÇ ¿µÇâ
  • monoclonal antibody
    ´ÜÀÏ Å¬·Ð Ç×ü
  • HY antigen
    H-YÇ׿ø(Y¿°»öü À¯ÀüÀÚ¿¡ ÀÇÁ¸ÇÏ´Â Á¶Á÷ ÀûÇÕ Ç׿ø)
  • Rhesus factor(antigen)
    =RH FACTOR
  • antigen
    Ç׿ø(Ç÷¾×Áß¿¡ antibodyÀÇ Çü¼ºÀ» ÃËÁøÇÏ´Â ¹°Áú)
  • histiocompatibility antigen
    Á¶Á÷ ÀûÇÕ¼º Ç׿ø
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á